Our future growth and value generation is based on increasing revenues from our two marketed anti-infectives and our innovative pipeline

Investing in Basilea

  • Growing revenues: we continue to grow revenues from Cresemba and Zevtera, including launches in further markets
  • Building global brands: we strengthen and fully exploit the commercial potential from our marketed products. Our commercialization partnerships cover more than 100 countries
  • Solid cash position: allows us to explore opportunities to selectively expand our pipeline through in-licensing and internal research and development
  • Growth potential: we are focused on advancing and expanding our R&D portfolio to create sustainable shareholder value

Convertible bonds

In July 2020, Basilea issued CHF 97.085 million convertible bonds due 2027 ("New Bonds", ISIN: CH0554992062; SSN: 55'499'206) and repurchased CHF 47.085 million of its CHF 200 million existing convertible bonds due 2022 ("Existing Bonds", ISIN: CH0305398148; SSN: 30'539'814). Through these transactions, the Company significantly improved its debt maturity structure.

Read more

For relevant information relating to convertible bonds of Basilea Pharmaceutica Ltd., please click here

Transaction Reporting regarding Bond Repurchase

Reporting under Section 5 of TOB Circular No. 1

Information for Shareholders and Bondholders of Basilea Pharmaceutica AG

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Letter of the chairman regarding the bond transaction

For German Version click here

Basel, Switzerland, June 25, 2020

Dear Shareholders, dear Bondholders

By this letter, I wish to inform you about a financial transaction of the Company.

Basilea Pharmaceutica AG ("Basilea") has convertible bonds outstanding in the aggregate principal amount of CHF 200 million ("Existing Bonds"). The Existing Bonds are due in December 2022.

Basilea intends to improve its debt maturity profile by:

  • repurchasing at least CHF 90 million and a maximum of CHF 110 million of the Existing Bonds in a repurchase offer ("Repurchase Offer"); and
  • issuing new convertible bonds ("New Bonds") in the aggregate principal amount of at least CHF 100 million and a maximum of CHF 125 million due in 2027 (subject to an investor put in 2025).

This combined transaction would extend approximately half of Basilea's debt maturity by five years (subject to an investor put in 2025).

The offer to repurchase Existing Bonds and the offer to sell New Bonds are dependent on each other and run in parallel.

The offer price in the Repurchase Offer amounts to 100.50% of the par-value of the Existing Bonds (or CHF 5'025 per Existing Bond with a par-value of CHF 5'000) plus accrued and unpaid interest up to the settlement date. The price is 1.01% above the price of the Existing Bonds as indicated on the website of SIX Swiss Exchange for 23 June 2020, i.e. before announcement of the intention to repurchase Existing Bonds.

The tender offer period during which the Repurchase Offer can be accepted is expected to start on July 10 and end on July 16, 2020, at 4 pm CEST (custodian agents may shorten this deadline for their clients). The settlement of the Repurchase Offer and of the New Bond issue is expected to take place on or about July 28, 2020.

The terms of both the Repurchase Offer and the New Bond issue are subject to jurisdictional restrictions and the terms are set out in separate definitive offer documentation.

Yours sincerely,

Basilea Pharmaceutica AG

Domenico Scala

Chairman of the Board

 

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

 

Information der Aktionäre und Obligationäre der Basilea Pharmaceutica AG

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Brief des Verwaltungsratspräsidenten zur Bondtransaktion

Basel, 25. Juni 2020

Sehr geehrte Aktionäre, sehr geehrte Obligationäre,

Mit diesem Brief möchte ich Sie über eine Finanztransaktion der Gesellschaft informieren.

Basilea Pharmaceutica AG („Basilea“) hat eine Wandelanleihe im Gesamtnennbetrag von CHF 200 Millionen ausstehend („Bestehende Anleihe“). Die Bestehende Anleihe ist im Dezember 2022 fällig.

Basilea beabsichtigt, das Fälligkeitsprofil ihres Fremdkapitals zu verbessern mittels

  • Rückkauf von mindestens CHF 90 Millionen und maximal CHF 110 Millionen der Bestehenden Anleihe in einem Rückkaufsangebot („Rückkaufangebot“); und
  • Ausgabe einer neuen Wandelanleihe („Neue Anleihe“) im Gesamtnennwert von mindestens CHF 100 Millionen und maximal CHF 125 Millionen mit Fälligkeit 2027 (vorbehaltlich einer Put-Option der Anleger im Jahr 2025).

Diese kombinierte Transaktion verlängert die Fälligkeit von ungefähr der Hälfte des Fremdkapitals der Basilea um fünf Jahre (vorbehaltlich einer Put-Option der Anleger im Jahr 2025).

Das Angebot zum Rückkauf eines Teils der bestehenden Anleihe und das Angebot zum Verkauf der Neuen Anleihe sind voneinander abhängig und laufen parallel zueinander.

Der Angebotspreis des Rückkaufangebots beträgt 100.50 % des Nennwerts jeder Obligation der Bestehenden Anleihe (oder CHF 5'025 pro Obligation der Bestehenden Anleihe mit einem Nennwert von CHF 5'000) zuzüglich aufgelaufener und bis zum Abwicklungstag nicht bezahlter Zinsen. Der Preis liegt 1.01 % über dem Kurs der Obligationen der Bestehenden Anleihe, wie er auf der Webseite der SIX Swiss Exchange für den 23. Juni 2020 angegeben ist, d.h. vor der Ankündigung der Absicht, die Bestehende Anleihe zurückzukaufen.

Die Angebotsfrist, in der das Rückkaufangebot angenommen werden kann, beginnt voraussichtlich am 10. Juli und endet am 16. Juli 2020 um 16 Uhr MESZ (Depotbanken können diese Frist für ihre Kunden verkürzen). Die Abwicklung des Rückkaufangebots und der Emission der Neuen Anleihe wird voraussichtlich am oder um den 28. Juli 2020 erfolgen.

Die Bedingungen sowohl des Rückkaufangebots als auch der Emission der Neuen Anleihe unterliegen rechtlichen Beschränkungen. Die Bedingungen sind in einer separaten, endgültigen Angebotsdokumentation dargelegt.

Mit freundlichen Grüßen,

Basilea Pharmaceutica AG

Domenico Scala

Präsident des Verwaltungsrats

 

Über Basilea

Basilea Pharmaceutica AG ist ein biopharmazeutisches Unternehmen mit vermarkteten Produkten, das sich auf die Entwicklung von Medikamenten zur Lösung der medizinischen Herausforderungen in den Therapiebereichen Onkologie und Infektionskrankheiten fokussiert. Basilea hat zwei vermarktete Produkte im Portfolio und erforscht, entwickelt und vermarktet innovative Medikamente für Patienten, die an schweren und lebensbedrohlichen Krankheiten leiden. Basilea Pharmaceutica AG hat ihren Hauptsitz in Basel, Schweiz, und ist an der Schweizer Börse SIX Swiss Exchange kotiert (SIX: BSLN). Für weitere Informationen besuchen Sie bitte die Unternehmens-Website www.basilea.com.

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy or tender securities of the Company and it does not constitute a prospectus or a similar notice within the meaning of article 652a, article 752 and/or article 1156 of the Swiss Code of Obligations or within the meaning of the Swiss Financial Services Act or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

THIS COMMUNICATION IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN. THIS COMMUNICATION DOES NOT CONSTITUTE AN OFFER TO SELL, OR THE SOLICITATION OF AN OFFER TO BUY, SECURITIES IN ANY JURISDICTION IN WHICH IS UNLAWFUL TO DO SO. IN PARTICULAR, THIS COMMUNICATION IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION UNDER THE U.S. SECURITIES ACT OF 1933 OR AN EXEMPTION FROM REGISTRATION. THE SECURITIES REFERRED TO IN THIS COMMUNICATION HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT AND WILL NOT BE PUBLICLY OFFERED OR SOLD IN THE UNITED STATES. THE REPURCHASE OFFER IS NOT BEING MADE IN THE UNITED STATES.

This communication does not constitute an "offer of securities to the public" within the meaning of Regulation 2017/1129 of the European Union (the "Prospectus Regulation") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Regulation, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.

This communication expressly or implicitly contains certain forward-looking statements concerning the Company and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102
media_relations@basilea.com 
investor_relations@basilea.com 
 

 

Current presentation

Updated April 9, 2024

Download

 

 

 

 

 

Events and presentations

Sep 24. 2024
HBM Biopharma Summit 2024, Zurich
Sep 23. 2024
Baader Investment Conference 2024, Munich
Sep 19. 2024
Pareto Securities' 15th Annual Healthcare Conference, Stockholm
Aug 13. 2024
2024 Half-year results and publication of half-year report 2023
Apr 11. 2024
Basilea's Capital Markets Day 2024, Zurich

"Creating anti-infectives opportunities": You can find the video recording and the presentation slides on the event website.
Basilea CMD website

 

Archive

Annual General Meeting

Apr 24. 2024, 14:00 CEST
Congress Center Basel in Basel, Switzerland
2024 Annual General Meeting of Shareholders

 

Archive

Analyst coverage

The analysts listed on this page have published reports or commentary on Basilea; there may be other analysts who have published reports or commentary that are not referenced here.  Please note that any opinions, estimates or forecasts regarding Basilea's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Basilea or its management.  Basilea does not by its reference on this website imply any endorsement of or concurrence with such information, conclusions or recommendations.

FIRM ANALYST
Baader Helvea AG Leonildo Delgado
Bryan Garnier & Co. Oscar Haffen Lamm
Calvine Partners LLP Brian White
Edison Investment Research Ltd. Soo Romanoff
H. C. Wainwright & Co. Raghuram Selvaraju
Kepler Cheuvreux Christophe Dombu
Pareto Securities AB Chien-Hsun Lee & Dan Akschuti
Zürcher Kantonalbank Edouard Riva

 

Share information

Sustainability (ESG)

At Basilea, we have performed a materiality analysis that helps us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model. These material topics form the basis of our ESG strategy. They will be key for the setting of goals and become the core of our future ESG-related reporting. 

Key elements of Basilea's ESG strategy

Corporate Governance